Bio-Rad Acquires Curiosity Diagnostics from Scope Fluidics
Posted on 05 Aug 2022
Bio-Rad Laboratories (Hercules, CA, USA) has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (Warsaw, Poland) for a total consideration of up to USD 170 million, consisting of approximately USD 100 million in cash, and up to USD 70 million in future milestone payments.
Curiosity Diagnostics, a late-stage, pre-commercial platform company, is in the process of developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market.
“We are excited to have the Curiosity Diagnostics team join Bio-Rad’s Clinical Diagnostics Group and to work closely together to bring a new generation of rapid PCR systems to market,” said Dara Wright, Bio-Rad’s EVP and President, Clinical Diagnostics Group. “Curiosity’s PCR platform, PCR|ONE, offers a streamlined workflow and rapid turnaround times, and is expected to extend our reach beyond high-complexity labs into near-patient molecular diagnostics labs.”
“Our passion at Scope Fluidics is developing innovative technologies addressing the greatest challenges in global health,” added Scope Fluidics President and co-founder, Professor Piotr Garstecki. “The dedicated, entrepreneurial team of highly skilled, specialized personnel of Curiosity Diagnostics is looking forward to further developing the PCR|ONE technology under Bio-Rad’s leadership while we at Scope Fluidics continue to pursue new and current projects in disruptive medical diagnostics.”
Related Links:
Bio-Rad Laboratories
Scope Fluidics, S.A.
